Arcutis Presents Infant ZORYVE Trial Results as FDA Review Continues
Arcutis Biotherapeutics presented results from the INTEGUMENT-INFANT study of ZORYVE cream 0.05% in 101 infants with mild to moderate atopic dermatitis on November 13, 2026. Caregivers reported itch improvement for 66.7% of infants within 4 hours, while the study found no serious adverse events. Arcutis is seeking approval for use in infants aged 3 to 24 months, and the FDA review has a target decision date of February 23, 2027.
Why it matters
The data support Arcutis's effort to expand ZORYVE's approved pediatric use beyond children aged 2 to 5 years. FDA action by February 23, 2027, will determine whether the product can be marketed for infants aged 3 to 24 months.
Key facts
- 1The trial enrolled 101 infants with mild to moderate atopic dermatitis. investing.com
- 2Caregivers reported at least 25% itch improvement in 46.6% of infants within 10 minutes after the first application and in 66.7% after 4 hours. investing.com
- 3The Worst Scratch Intensity Numerical Rating Scale success rate was 72.7% at the final assessment. investing.com
- 4Mean Patient-Oriented Eczema Measure scores fell from 14.5 initially to 7.9 at Week 2 and 6.5 at Week 4. investing.com
- 5Arcutis's supplemental New Drug Application covers infants aged 3 to 24 months and has an FDA target action date of February 23, 2027. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.